 Ranibizumab has been reimbursed for the treatment of nAMD by the Taiwan National Health Insurance Bureau NHIB since 2012, with a total reimbursement of 3 or 7 injections for each eye depending on the clinical response of the patient in his or her lifetime, after which, the treatment is paid by the patients themselves. In order to be reimbursed by the NHIB, patients must be at least 50 years old at the time of diagnosis, and had nAMD confirmed by fluorescein angiography, with subretinal fluid or macular edema demonstrated by optical coherence tomography OCT. In addition, there should be no macular scars on the fovea, and the best correct decimal visual acuity BCVA should be ranging between 0.05 to 0.5. The waiting period for the permission of reimbursement of ranibizumab was around 4 weeks, thus some patients would have a self-paid bevacizumab injection during the waiting period. 